Seda Tolu, MD
Hematology & Oncology · New York, NYNPI 1851825095
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,391 of the $1,557 with a category attached, or 89.3%. 10 manufacturers reported payments, led by Pfizer at 29.2% of the total. 2025 is the largest year on record at $557, 2.5 times the $224 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 20 payments — averaging $77.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$455
- AstraZeneca$282
- AbbVie$181
- Daiichi Sankyo Inc.$125
- Kyowa Kirin, Inc.$121
- Sanofi$113
- plus $280 from 4 others
What the payments were for
- Food & beverage$1,39189%
- Education$16611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $455 |
| AstraZeneca | 4 | $282 |
| AbbVie | 4 | $181 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $121 |
| Sanofi | 1 | $113 |
| Incyte Corporation | 1 | $99 |
| ADC Therapeutics America, Inc. | 1 | $90 |
| Regeneron | 1 | $77 |
| Beigene USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADCETRIS$245
- INJECTAFER$125
- POTELIGEO$121
- EPKINLY$118
- ENJAYMO$113
How this compares
$1,557 in reported general payments places this provider in the 50th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.